Toru Tateno

Dr. Toru Tateno

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
TNTae Nakano-Tateno
Tae Nakano-Tateno
KLKheng Joe Lau
Kheng Joe Lau
JWJustin Wang
Justin Wang
CMCailin McMahon
Cailin McMahon
YKYasuhiko Kawakami
Yasuhiko Kawakami
TATakako Araki
Takako Araki
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.

31 December 2023 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
EWElizabeth Whyte
Elizabeth Whyte
MNMasahiro Nezu
Masahiro Nezu
CCConstance Chik
Constance Chik
TTToru Tateno
Toru Tateno
Pituitary neuroendocrine tumors (PitNETs) are the third most frequently diagnosed intracranial tumors, with nonfunctioning PitNETs (nfPitNETs) accounting for 30% of all pituitary tumors and representing the most common type of macroPitNETs. NfPitNETs are usually benign tumors with no evidence of hormone oversecretion except for hyperprolactinemia secondary to pituitary stalk compression. Due to this, they do not typically present with clinical syndromes like acromegaly, Cushing’s disease or hyperthyroidism and instead are identified incidentally on imaging or from symptoms of mass effects (headache, vision changes, apoplexy). With the lack of effective medical interventions, first-line treatment is transsphenoidal surgical resection, however, nfPitNETs often have supra- or parasellar extension, and total resection of the tumor is often not possible, resulting in residual tumor regrowth or reoccurrence. While functional PitNETs can be easily followed for recurrence using hormonal biomarkers, there is no similar parameter to predict recurrence in nfPitNETs, hence delaying early recognition and timely management. Therefore, there is a need to identify prognostic biomarkers that can be used for patient surveillance and as therapeutic targets. This review focuses on summarizing the current evidence on nfPitNETs, with a special focus on potential new biomarkers and therapeutics.

1 September 2020 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MSMotoyasu Satou
Motoyasu Satou
JWJason Wang
Jason Wang
TNTae Nakano-Tateno
Tae Nakano-Tateno
MTMariko Teramachi
Mariko Teramachi
TSTokiko Suzuki
Tokiko Suzuki
TTToru Tateno
Toru Tateno

1 January 2006 in Internal Medicine
Verified
Journal Article
Open access
PDF file
IMIsao Minami
Isao Minami
TTToru Tateno
Toru Tateno
TYTakanobu Yoshimoto
Takanobu Yoshimoto
MDMasaru Doi
Masaru Doi
HIHajime Izumiyama
Hajime Izumiyama
YHYukio Hirata
Yukio Hirata
A 49-year-old woman with hypertension, obesity and impaired glucose tolerance (IGT) was admitted for evaluation of pituitary incidentaloma. Although she presented no Cushingoid feature, endocrine examination of hypothalamo-pituitary-adrenal (HPA) axis showed elevated basal plasma ACTH and cortisol levels, their lack of circadian rhythm, non-suppressibility to low-dose (1 mg) dexamethasone, and responsiveness to CRH, suggesting autonomous ACTH secretion from a pituitary tumor. She underwent transsphenoidal surgery, and was diagnosed as chromophobe adenoma with positive ACTH immunoreactivity. Postoperatively, her abnormal HPA axis was resolved, along with improvement of hypertension, obesity and IGT. Thus, her metabolic comorbidities are likely due to subclinical Cushings disease.

8 March 2024 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
MSMotoyasu Satou
Motoyasu Satou
JWJason Wang
Jason Wang
TNTae Nakano-Tateno
Tae Nakano-Tateno
MTMariko Teramachi
Mariko Teramachi
SAShigeki Aoki
Shigeki Aoki
TTToru Tateno
Toru Tateno

16 September 2025 in Cells
Verified
Journal Article
Open access
PDF file
TTToru Tateno
Toru Tateno
MSMariam Shahidi
Mariam Shahidi
JLJian-Qiang Lu
Jian-Qiang Lu
CCConstance Chik
Constance Chik
The immune landscape plays an important role in various pituitary diseases, ranging from hypophysitis to pituitary neuroendocrine tumors. Moreover, the use of immune checkpoint inhibitors (ICIs) has dramatically altered the landscape of cancer treatment by improving prognosis and overall survival in a multitude of advanced-staged malignancies, though their use in pituitary neuroendocrine tumors has remained limited. In this review, we will focus on selected topics to highlight the impact of the immune microenvironment on the function of the pituitary gland, namely, animal models of autoimmune hypophysitis, including ICI-induced hypophysitis as a common adverse event, and the importance of its early recognition in patients treated with ICIs. Using a case, we will provide an overview on the epidemiology, pathogenesis, clinical spectrum, diagnosis, predictors, and management of ICI-induced hypophysitis. We will also summarize the role of the immune microenvironment in pituitary neuroendocrine tumors with programmed cell death ligand 1 as a biomarker for treatment. Lastly, we will review the role of ICIs in the management of 40 patients with aggressive and metastatic pituitary neuroendocrine tumors. Current knowledge gaps in these topics will also be highlighted.